Alkermes (NASDAQ:ALKS – Get Free Report) is scheduled to be posting its quarterly earnings results before the market opens on Thursday, October 24th. Analysts expect Alkermes to post earnings of $0.76 per share for the quarter. Alkermes has set its FY 2024 guidance at 2.800-2.800 EPS.
Alkermes (NASDAQ:ALKS – Get Free Report) last issued its quarterly earnings results on Wednesday, July 24th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. The company had revenue of $399.13 million for the quarter, compared to the consensus estimate of $393.30 million. Alkermes had a return on equity of 23.20% and a net margin of 19.15%. The company’s revenue for the quarter was down 35.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.38 EPS. On average, analysts expect Alkermes to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Alkermes Stock Performance
NASDAQ:ALKS traded down $0.17 during trading hours on Friday, hitting $28.16. 45,654 shares of the company traded hands, compared to its average volume of 1,816,418. The company has a current ratio of 2.99, a quick ratio of 2.61 and a debt-to-equity ratio of 0.22. Alkermes has a twelve month low of $22.01 and a twelve month high of $32.88. The firm has a 50-day moving average of $27.71 and a 200 day moving average of $25.83. The stock has a market capitalization of $4.77 billion, a price-to-earnings ratio of 11.26, a P/E/G ratio of 0.56 and a beta of 0.46.
Analysts Set New Price Targets
Read Our Latest Stock Analysis on Alkermes
About Alkermes
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Read More
- Five stocks we like better than Alkermes
- Why Are Stock Sectors Important to Successful Investing?
- Buy the Dip? UiPath Stock’s GenAI Strategy May Pay Off
- What is a Special Dividend?
- Global Lithium Demand Soars: Top 3 Stocks Positioned to Gain
- What is a SEC Filing?
- Oil Prices Fall, Sector Pulls Back: Time to Buy this Stock?
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.